热剂量可预测现代放化疗联合热疗宫颈癌患者局部控制
该研究纳入2005–2016年接受放疗联合深部热疗的原发宫颈癌患者227例,验证热剂量参数TRISE和CEM43T90与局部控制的关系。多因素分析显示组织学、FIGO分期、淋巴结转移、TRISE、CEM43T90和IGBT对局部控制有显著影响;在接受IGBT的患者中,TRISE仍与局部控制显著相关。
要点
- 热剂量参数TRISE和CEM43T90与宫颈癌局部控制显著相关
- 在接受IGBT的患者中TRISE对局部控制仍有显著影响
- 热剂量与临床结局的正相关在独立近期队列中得到重复验证
核心结论
- 热剂量与临床结局的正相关在独立的近期宫颈癌队列中得到重复验证。
- 在接受IGBT的患者中,热剂量对临床结局的影响仍然可以观察到。
研究设计与样本
- 分析2005–2016年在本机构接受放疗联合深部热疗的原发宫颈癌患者,共227例。
- 收集患者、肿瘤和治疗数据,包括热剂量参数TRISE和CEM43T90。
- 随访收集局部控制、无病生存、疾病特异性生存、总生存及晚期毒性数据。
- 采用Cox比例风险分析和Kaplan-Meier分析进行数据处理。
主要发现
- 多因素分析中,组织学、FIGO分期、淋巴结转移、TRISE、CEM43T90和IGBT对局部控制有显著影响。
- 在接受IGBT的患者中,热剂量参数TRISE在单因素分析中仍对局部控制有显著影响。
临床怎么用
- 在宫颈癌放疗联合深部热疗中,可将TRISE和CEM43T90作为热剂量参数加以关注。
- 即使采用包括IGBT在内的现代放疗技术,热剂量对局部控制的影响仍应予以重视。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Addition of deep hyperthermia results in improved local control (LC) and overall survival (OS) compared to radiotherapy alone in patients with cervical carcinoma. Previously, we showed that the thermal dose of hyperthermia significantly correlates with LC and disease specific survival (DSS). Over the last decade, new radiation techniques were introduced resulting in improved LC. AIM: To validate the effect of thermal dose in a more recent cohort of patients treated with modern radiotherapy techniques, including image guided brachytherapy (IGBT). METHODS: We analyzed primary cervical carcinoma patients treated with a combination of radiotherapy and deep hyperthermia between 2005 and 2016 at our institute. Data on patient, tumor and treatment were collected including the thermal dose parameters TRISE and CEM43T90. Follow-up data on LC, disease free survival, DSS, OS as well as late toxicity data were collected. Data were analyzed using the Cox proportional hazard and Kaplan-Meier analyses. RESULTS: 227 patients were included. In multivariate analysis, histology, FIGO stage, lymphadenopathy, TRISE, CEM43T90 and IGBT had a significant effect on LC. In the patients treated with IGBT, the thermal dose parameter TRISE remained to have a significant effect on LC in univariate analysis. CONCLUSIONS: The positive association between thermal dose and clinical outcome is replicated in an independent, recent cohort of cervical carcinoma patients. Importantly, in patients receiving IGBT, the effect of thermal dose on clinical outcome is still observed.
引用
- Kroesen M, Mulder HT, van Holthe JML, et al. Confirmation of thermal dose as a predictor of local control in cervical carcinoma patients treated with state-of-the-art radiation therapy and hyperthermia. Radiother Oncol. 2019. PMID: 31302345. doi:10.1016/j.radonc.2019.06.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。